431 filings
Page 8 of 22
DEFA14A
74hy4pv8pv2c07vt
11 May 20
Additional proxy soliciting materials
7:55am
UPLOAD
gim56vnamv y0c
7 May 20
Letter from SEC
12:00am
8-K
mm7jqp19 f8qfzc
24 Mar 20
Onconova Therapeutics Announces Completion of Enrollment of Phase 3 INSPIRE Trial, Provides a Corporate Update, and Reports 2019 Financial Results
4:10pm
SEC STAFF
744ay37ix
19 Feb 20
SEC staff action: Order
12:00am
SEC STAFF
2s9oj
7 Feb 20
SEC staff action: Order
12:00am
8-K
cqr t3oy3p
23 Jan 20
Termination of a Material Definitive Agreement
8:38am
8-K
b4rs0zw k3z
17 Jan 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:26pm
8-K
6m2kr 46yyg1203hx24s
3 Jan 20
Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market
5:29pm
424B5
d3ip9u2 9b3dg
3 Jan 20
Prospectus supplement for primary offering
9:28am
8-K
audej g83
19 Dec 19
Onconova Therapeutics, Inc. Announces Closing Of $5.0 Million Registered Direct Offering Priced At-The-Market
4:16pm
424B5
493k6e97puhm19j7a
19 Dec 19
Prospectus supplement for primary offering
9:22am
8-K
lj43hyjhfnjfvvjgj2l
19 Dec 19
Onconova Therapeutics Announces Exclusive License Agreement with Specialised Therapeutics for Rigosertib in Australia and New Zealand
9:19am
8-K
icfl eujoffke
19 Dec 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:07am
8-K
1mn1voi5
10 Dec 19
Onconova Therapeutics, Inc. Announces $5.0 Million Registered Direct Offering Priced At-the-Market
11:19am
424B5
yg0 7y0g3q
10 Dec 19
Prospectus supplement for primary offering
8:02am
8-K
6hjz 016eo1bce1
9 Dec 19
Regulation FD Disclosure
9:07am